Brief: Palisade Bio Reports 100% Response in Phase 1b Ulcerative Colitis Trial of PALI-2108
07/08/2025 14:25
Aug 7 (Reuters) - Palisade Bio Inc PALI.O: PALISADE BIO REPORTS 100% CLINICAL RESPONSE IN PHASE 1B ULCERATIVE COLITIS COHORT WITH NOVEL PDE4 INHIBITOR, PALI-2108 PALISADE BIO INC - PALI-2108 SAFE AND WELL TOLERATED WITH NO SERIOUS ADVERSE EVENTS PALISADE BIO INC - TO SUBMIT IND FOR PHASE 2 STUDY IN H1 2026 Source text: ID:nGNX4CgWn0 Further company coverage: PALI.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Palisade Bio
See all newsPalisade Bio Inc reports results for the quarter ended June 30 - Earnings Summary
Palisade Bio Q2 net loss widens on higher R&D costs
Brief: Palisade Bio Q2 EPS USD -0.05
Palisade Bio Inc expected to post a loss of 5 cents a share - Earnings Preview
Brief: Palisade Bio Inc - May Offer And Sell Up To $300 Million Of Securities - SEC Filing